Myocardial Infarction (MI) Therapeutics - Pipeline Assessment

Jan. 3, 2012 - PRLog -- GlobalData’s has estimated that the global MI therapeutics market was valued $3,904.3m in 2005, before increasing at a Compound Annual Growth Rate (CAGR) of 5.9% to reach $5,204.0m in 2010. The market is expected to increase slowly, to $5,384.3m by 2018, at a CAGR of 0.4%. The slow growth in the forecast period can be attributed to the patent expiry of some of the major marketed products such as
Lipitor (atorvastatin), Plavix / Iscover (clopidogrel) in late 2011 (in the US, it has now expired in the European countries), Effient / Efient (prasugrel), Integrilin (eptifibatide), Aggrastat (tirofiban) in 2012 and Crestor (rosuvastatin) in 2016. The patent expiries will attract generic versions of these drugs to the market. However, the expected approval and launch of novel first-in-class molecules such as varespladib methyl from Anthera Pharmaceuticals, darapladib from GlaxosmithKline, otamixaban from Sanofi, Xarelto (rivaroxaban) from Bayer AG, cangrelor from The Medicines Company and elinogrel (PRT128) from Novartis AG / Portola Pharmaceuticals Inc., would restrain the impact of these expiries. The pipeline contains novel molecules whose cost of treatment is expected to be high, therefore the market penetration of these molecules will be slow in the initial years. In summary, the MI therapeutics market is expected to witness slow growth with generics playing a major role in the forecast period, this is similar to the present market scenario.

GlobalData assessed the current MI therapeutics market to be a weak but competitive market. The market is populated by branded drugs, generics and many off label usage of drugs both for the management and treatment of MI. Although, the market has various treatment options, they are only moderately successful in meeting market demand - none of the treatment options are able to manage the condition completely. The current treatment options have moderate efficacy and safety profiles, they also offer poor quality of life due to their lack of efficacy in reducing cardiovascular events and mortality. At present in the oral platelet-aggregation inhibitors class of drugs Plavix / Iscover and Aspirin have a significant market share. Effient/ Efient of Daiichi Sankyo/ Eli Lilly's is the most advanced therapy in Non– ST-Segment Elevation, Myocardial Infarction (NSTEMI). The drug is expected to have little impact in the market because of its mixed results in the TRITON-TIMI-38 clinical trial. However, beta blockers, calcium channel blockers, Angiotensin Converting Enzymes (ACE) inhibitors, antithrombolytics, Angiotensin II receptor blockers (ARBs), statins and nitrates are also used in MI patients as primary or secondary prevention and these drugs are expected to maintain a significant market share.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

In the market three Glycoprotein (GP) IIb/IIIa inhibitors are present namely Aggrastat, Integrilin and
Reopro (abciximab). Of these, Aggrastat has shown positive long-term results, however, ReoPro is still clinically relevant in the short-term and it is the drug of choice for MI patients in Percutaneous Coronary Intervention (PCI) settings. Aggrastat and Integrilin are less costly compared with ReoPro and Integrili costs more compared to Aggrastat. These agents are mainly used in patients with recurrent ischemia who are undergoing interventional treatment.

GlobalData, the industry analysis specialist, has released its new report, “Myocardial Infarction (MI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global MI therapeutics market. The report identifies the key trends shaping and driving the global MI therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the position of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global MI sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Myoc...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.